US2003060625A1PendingUtilityA1

Para-amine substituted phenylamide glucokinase activators

Priority: May 8, 2000Filed: Sep 26, 2002Published: Mar 27, 2003
Est. expiryMay 8, 2020(expired)· nominal 20-yr term from priority
C07D 213/82C07D 417/12C07D 277/46
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Para-alkyl, aryl, cycloheteroalkyl or heteroaryl [carbonyl or sulfonyl] amino substituted phenyl amides active as glucokinase activators to increase insulin secretion which makes them useful for treating type II diabetes.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . An amide selected from the group consisting of a compound of the formula  
       
         
           
           
               
               
           
         
       
       wherein X is  
       
         
           
           
               
               
           
         
       
       wherein R is perfluoro-lower alkyl, lower alkyl,  
       
         
           
           
               
               
           
         
       
       lower alkoxycarbonyl, a heteroaromatic ring, connected by a ring carbon atom, containing from 5 to 6 ring members with from 1 to 3 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, unsubstituted aryl containing 6 or 10 ring carbon atoms, a nitro or a lower alkyl substituted aryl which aryl contains 6 or 10 ring carbon atoms or a saturated 5- or 6-membered cycloheteroalkyl ring, connected by a ring carbon atom, containing from 1 to 2 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur or cycloalkyl having 5 or 6 carbon atoms; R 1  is cycloalkyl having 5 or 6 carbon atoms; R 2  is a five- or six-membered heteroaromatic ring connected by a ring carbon atom to the amide group to the remainder of the compound, which heteroaromatic ring contains from 1 to 3 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen with a first heteroatom being nitrogen which is adjacent to the connecting ring carbon atom, said heteroaromatic ring being unsubstituted or monosubstituted at a position on a ring carbon atom other than adjacent to said connecting carbon atom with a substituent selected from the group consisting of lower alkyl, or  
       
         
           
           
               
               
           
         
       
       n and y are independently an integer from 1 to 4; R 4 , R 5  and R 7  are independently hydrogen or lower alkyl; and * denotes the asymmetric carbon atom and a pharmaceutically acceptable salt thereof.  
     
     
         2 . The amide of  claim 1  wherein said compound is  
       
         
           
           
               
               
           
         
       
       wherein R, R 1 , R 2  and y are as above.  
     
     
         3 . The amide of  claim 2  wherein R 1  is cyclopentyl.  
     
     
         4 . The amide of  claim 4  wherein R 2  is a substituted or unsubstituted five-membered heteroaromatic ring.  
     
     
         5 . The amide of  claim 4  wherein R is aryl substituted with a nitro group.  
     
     
         6 . The amide of  claim 5  wherein said compound is N-{4-[2-cyclopentyl-1-(thiazol-2-ylcarbamoyl)-ethyl]-phenyl}-4-nitro-benzamide.  
     
     
         7 . The amide of  claim 4  wherein R is unsubstituted aryl.  
     
     
         8 . The amide of  claim 7  wherein said compound is N-{4-[2-cyclopentyl-1-(thiazol-2-ylcarbamoyl)-ethyl]-phenyl}-benzamide.  
     
     
         9 . The amide of  claim 4  wherein R is said heteroaromatic ring.  
     
     
         10 . The amide of  claim 9  wherein said compound is 3-cyclopentyl-N-thiazol-2-yl-2-[4-(2-thiophen-2-yl-acetylamino)-phenyl]-propionamide.  
     
     
         11 . The amide of  claim 9  wherein said compound is N-{4-[2-cyclopentyl-1-(thiazol-2-ylcarbamoyl)-ethyl]-phenyl}-isonicotinamide.  
     
     
         12 . The amide of  claim 9  wherein said compound is 2-(3-cyclopentyl-2-{4-[(pyridine-3-carbonyl)-amino]-phenyl}-propionylamino)-thiazole-4-carboxylic acid ethyl ester.  
     
     
         13 . The amide of  claim 9  wherein said compound is N-{4-[2-cyclopentyl-1-(thiazol-2-ylcarbamoyl)-ethyl]-phenyl}-nicotinamide.  
     
     
         14 . The amide of  claim 9  wherein said compound is [2-(3-cyclopentyl-2-{4-[(pyridine-3-carbonyl)-amino]-phenyl}-propionylamino)-thiazol-4-yl]-acetic acid ethyl ester.  
     
     
         15 . The amide of  claim 3  wherein R 2  is a substituted or unsubstituted 6-membered heteroaromatic ring.  
     
     
         16 . The amide of  claim 15  wherein R is unsubstituted aryl or heteroaromatic ring.  
     
     
         17 . The amide of  claim 16  wherein said compound is N-{4-[2-cyclopentyl-1-(pyridin-2-ylcarbamoyl)-ethyl]-phenyl}-nicotinamide.  
     
     
         18 . The amide of  claim 16  wherein said compound is 6-(3-cyclopentyl-2-{4-[(pyridine-3-carbonyl)-amino]-phenyl}-propionylamino)-nicotinic acid methyl ester.  
     
     
         19 . The amide of  claim 16  wherein said compound is 6-(3-cyclopentyl-2-{4-[(pyridine-3-carbonyl)-amino]-phenyl}-propionylamino)-nicotinic acid.  
     
     
         20 . The amide of  claim 4  wherein R is lower alkoxy carbonyl.  
     
     
         21 . The amide of  claim 20  wherein said compound is N-{4-[2-cyclopentyl-1-(thiazol-2-ylcarbamoyl)-ethyl]-phenyl}-oxalamic acid methyl ester.  
     
     
         22 . The amide of  claim 20  wherein said compound is acetic acid {4-[2-cyclopentyl-1-(thiazol-2-ylcarbamoyl)-ethyl]-phenylcarbamoyl}-methyl ester.  
     
     
         23 . The amide of  claim 1  wherein said compound is  
       
         
           
           
               
               
           
         
       
       wherein R, R 1 , R 2  and y are as above.  
     
     
         24 . The compound of  claim 23  wherein R 1  is cyclopentyl.  
     
     
         25 . The amide of  claim 24  wherein R 2  is a 5-membered heterocyclic ring.  
     
     
         26 . The amide of  claim 25  wherein R 2  is thiazolyl.  
     
     
         27 . The amide of  claim 26  wherein R is lower alkyl or perfluorolower alkyl.  
     
     
         28 . The amide of  claim 27  wherein said compound is 3-cyclopentyl-2-(4-methanesulfonylamino-phenyl)-N-thiazol-2-yl-propionamide.  
     
     
         29 . The amide of  claim 27  wherein said compound is 3-cyclopentyl-N-thiazol-2-yl-2-(4-trifluoromethanesulfonylamino-phenyl)-propionamide.  
     
     
         30 . The amide of  claim 27  wherein said amide is 3-cyclopentyl-N-thiazol-2-yl-2-[4-(2,2,2-trifluoro-ethanesulfonylamino)-phenyl]-propionamide.  
     
     
         31 . The amide of  claim 26  wherein R is  
       
         
           
           
               
               
           
         
       
       wherein R 4  and R 5  are as above.  
     
     
         32 . The amide of  claim 26  wherein R is aryl or nitro substituted aryl.  
     
     
         33 . The amide of  claim 33  wherein said compound is 3-cyclopentyl-2-[4-(4-nitro-benzenesulfonylamino)-phenyl]-N-thiazol-2-yl-propionamide.

Join the waitlist — get patent alerts

Track US2003060625A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.